Headache and Migraine

The randomized, double-blind, placebo-controlled trial will enroll approximately 2900 people with migraine and will evaluate the efficacy and safety of 100- and 200-mg zavegepant.

Neurology News Network for the week ending April 3, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 2, 2021.

Neurologist Jessica Ailani, MD, explains when she feels it is most appropriate to treat migraine more aggressively with prescription drugs versus with lifestyle intervention.

Jessica Ailani, MD, describes her approach to evaluating new patients for migraine and explains how her diagnostic work-up can impact her recommendations for treatment.

In the phase 3 ADVANCE trial, all active treatment arms of atogepant met their primary end point, and the 30-mg and 60-mg doses met all 6 secondary end points with statistical significance.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Brian Grosberg, MD.

The director of the Montefiore Headache Center discussed recent advances in treating migraine both acutely and preventively.

Types of foods and weather conditions that may trigger migraine attacks.

Recommendations for incorporating and adhering to lifestyle interventions that can help prevent migraine or reduce the severity of attacks.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 19, 2021.

A panel of healthcare professionals and patient advocates with migraine recognize the social stigma associated with the condition despite its prevalence in the community.

Philippa Cheetham, MD, and Jill Dehlin, RN, comment on the severity of migraine attacks and concerns that migraines may trigger more series events.

Here's what is coming soon to NeurologyLive.

The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.

Students share their experience in the virtual classroom, navigating new requirements, and the lessons learned from their position in a global pandemic.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 12, 2021.

In a study of more than 600 patients, single medication classes were overused by 70% of patients, and less than half of the cohort was taking a preventive treatment.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 5, 2021.